Last reviewed · How we verify
NCT04266522
Medical Physics Direct Patient Care for the Improvement of Patient Understanding of Care
NA trial testing Informational Intervention in Malignant Neoplasm in 45 participants. Completed in 30 September 2021.
30 September 2021
Quick facts
| Lead sponsor | Barbara Ann Karmanos Cancer Institute |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 45 |
| Start date | 16 January 2020 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Informational Intervention
- Counseling
- Questionnaire Administration
Conditions studied
- Malignant Neoplasm — all drugs for Malignant Neoplasm →
Sponsor
Barbara Ann Karmanos Cancer Institute
Who can join
18 and older, any sex, with Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well medical physics direct patient care works in improving patients' understanding of their cancer treatment. Providing direct physicist-patient interactions and answering patients' questions about their cancer treatment may help patients to understand the care and therefore reduce anxiety and distress during treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04266522
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Informational Intervention
Trials testing the same drug.
- NCT06977503 — Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers · NA · recruiting
- NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
- NCT06927947 — Navigation Interventions to Improve Cascade Genetic Testing Among Relatives of Patients With Hereditary Cancer Syndromes · NA · recruiting
- NCT06568016 — A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemi · NA · recruiting
- NCT06639958 — A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home · NA · suspended
Other recruiting trials for Malignant Neoplasm
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
- NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
Other Barbara Ann Karmanos Cancer Institute trials
Trials by the same sponsor.
- NCT07343297 — Ask Questions About Clinical Trials · NA · not yet recruiting
- NCT07118202 — TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma · NA · recruiting
- NCT07098299 — Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies · Phase 1 · recruiting
- NCT07130903 — Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Met · Phase 2 · recruiting
- NCT07095114 — A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04266522 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Barbara Ann Karmanos Cancer Institute
- Last refreshed: 7 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04266522.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing